Three primary approaches exist for elevating NAD+ levels in research: oral nicotinamide mononucleotide (NMN), oral nicotinamide riboside (NR), and direct NAD+ injection. Each has fundamentally different pharmacokinetics, tissue distribution, and research applications.
The NAD+ Salvage Pathway
All three precursors feed into the NAD+ salvage pathway. NMN is converted to NAD+ by NMNAT enzymes. NR is converted to NMN by NRK1/2, then to NAD+ via NMNAT. Direct NAD+ injection bypasses salvage entirely — but requires a transporter (connexin 43 hemichannels or purinergic receptors) for cellular uptake. Understanding this pathway hierarchy is essential for interpreting tissue-specific effects.
Quick Comparison Table
| Parameter | NMN (Oral) | NR (Oral) | NAD+ (Injection) |
|---|---|---|---|
| Molecular mass | 334 Da | 255 Da | 663 Da |
| Oral bioavailability | ~5% (plasma) | ~15% (plasma) | <1% (oral) |
| Injection bioavailability | High (IP/SC) | High (IP/SC) | ~50% (IV) |
| Tissue NAD+ elevation | Liver, kidney, muscle | Liver, brain | Blood, liver |
| Cellular uptake | Slc12a8 transporter | Nucleoside transporters | Cx43/P2RY (limited) |
| Half-life in circulation | ~25 min | ~30 min | ~2–4 h (IV) |
| Primary metabolite | NAD+ via NMNAT | NMN via NRK | NAD+ (direct) |
Detailed Comparison
NMN (Nicotinamide Mononucleotide)
NMN is one step removed from NAD+ in the salvage pathway. It is converted to NAD+ by NMNAT enzymes — of which there are three isoforms with distinct tissue distributions. Oral NMN has limited but measurable bioavailability (~5%) due to rapid intestinal degradation and hepatic first-pass metabolism. The specific NMN transporter Slc12a8 in the small intestine facilitates some absorption. NMN's primary tissue effects are in the liver, kidney, and skeletal muscle — tissues with high NMNAT3 expression.
NR (Nicotinamide Riboside)
NR is the most orally bioavailable precursor (~15% plasma). Its smaller size allows passive diffusion and transporter-mediated absorption. NR requires conversion to NMN by NRK1/2 kinases — NRK1 is widely expressed, NRK2 is specific to skeletal muscle and brain. NR shows enhanced brain NAD+ elevation compared to NMN, likely due to NRK1 expression at the blood-brain barrier. NR is the most studied oral precursor in human clinical trials.
Direct NAD+ Injection
Direct NAD+ injection (IV, SC, or IM) provides the highest plasma NAD+ levels but faces the challenge of cellular uptake — NAD+ is a large, charged molecule that does not passively cross cell membranes. Uptake occurs via connexin 43 (Cx43) hemichannels and purinergic P2RY receptors. These channels are upregulated in metabolically active tissues and inflammatory states. Injection provides superior bioavailability for blood and liver NAD+ elevation but variable effects on tissue compartments with lower Cx43 expression.
Research Considerations
- For liver-specific NAD+ elevation: All three approaches are effective; NMN and NR show strong hepatic effects.
- For brain NAD+ elevation: NR is likely superior due to NRK1 at the blood-brain barrier.
- For skeletal muscle NAD+: NMN shows enhanced uptake via NMNAT3 in muscle.
- For maximal plasma NAD+: Direct NAD+ injection provides the highest peak levels.
- For long-term chronic protocols: Oral precursors are practical; injection is suited for high-dose acute protocols.
Which to Choose for Your Research?
If the research question involves muscle NAD+ metabolism, NMN is the best-characterised tool. For brain or CNS NAD+ research, NR's blood-brain barrier permeability is advantageous. For studies requiring rapid, high-level plasma NAD+ elevation (e.g., acute injury models, IV infusion protocols), direct NAD+ injection provides the most direct approach. The combination of an oral precursor with periodic injection is an emerging area of research for optimising both peak and baseline NAD+ levels.
This comparison is provided for research purposes only. All compounds are for laboratory use.
Element42 Peptides — NAD+ for injection research | NAD+ research guide